Replies to post #249802 on Amarin Corp Plc (AMRN)

[jomama9231]

I can’t comment more than they are saying in their conf calls regarding that.
Updated conf call is Monday.


“Matinas intends to initiate a number of studies, including a 28-day comparative bridging toxicology study and a comparative clinical bioavailability, further assessing PK parameters of MAT9001. These studies are designed to support a potential U.S. Food and Drug Administration (FDA) approval. The Company also plans to initiate an additional head-to-head study vs. Vascepa at beginning of 2020 and data expected in the 3q 2020”

They said they were submitting 2022 expected approval 2023 last I checked. Lots of time for trials. Funded well into 2021